Dr. Brown on PI3 Kinase Inhibitors in CLL | OncLive

Dr. Brown on PI3 Kinase Inhibitors in CLL

March 2, 2017

Jennifer Brown MD, PhD, director, Chronic Lymphocytic Leukemia Center, senior physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses PI3 kinase inhibitors in patients with chronic lymphocytic leukemia (CLL).

Jennifer Brown MD, PhD, director, Chronic Lymphocytic Leukemia Center, senior physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses PI3 kinase inhibitors in patients with chronic lymphocytic leukemia (CLL).

There are 2 drugs that inhibit PI3 kinase delta that are in registration trials, Brown explains. The first, duvelisib, also inhibits PI3 kinase gamma, meaning it can target T cells and neutrophils, which has had high activity in CLL.

The other drug, TGR-1202, has had to go through dosing modifications and be reformulated to achieve effective pharmacokinetics in patients. The number of patients on those doses and the duration is relatively limited but they have seen beneficial response rates, Brown states.


x